Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Vaginal estrogen may pose risks to patients taking new breast cancer drugs
February 14th, 2006
Breast cancer specialists from one of Great Britain's leading cancer centers caution doctors of the risks in prescribing vaginal estrogen to breast cancer patients being treated with the new aromatase inhibiting drugs, anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin). Their concerns follow findings from the first study to examine the impact of vaginal estrogen in women receiving aromatase inhibitors (AIs) for breast cancer, published January 26, 2006, online in Annals of Oncology by a team from the Royal Marsden NHS Foundation Trust in London. AIs work by inhibiting the enzyme aromatase, which promotes the conversion of...
Source: Cancer Weekly (2006-02-14)
|
